563 related articles for article (PubMed ID: 15831779)
1. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
5. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.
Trocóniz IF; Tillmann C; Liesenfeld KH; Schäfer HG; Stangier J
J Clin Pharmacol; 2007 Mar; 47(3):371-82. PubMed ID: 17322149
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
11. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Stangier J
Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers.
Tanaka M; Yamazaki H; Ryokawa Y; Hakusui H; Nakamichi N; Sekino H
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):415-9. PubMed ID: 8897077
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
15. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery.
Dansirikul C; Lehr T; Liesenfeld KH; Haertter S; Staab A
Thromb Haemost; 2012 Apr; 107(4):775-85. PubMed ID: 22398858
[TBL] [Abstract][Full Text] [Related]
16. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.
Koch HJ; Hartmann M; Bliesath H; Huber R; Steinijans VW; Mascher H; Wurst W
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):420-3. PubMed ID: 8897078
[TBL] [Abstract][Full Text] [Related]
17. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S58-66. PubMed ID: 8793604
[TBL] [Abstract][Full Text] [Related]
18. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
Blech S; Ebner T; Ludwig-Schwellinger E; Stangier J; Roth W
Drug Metab Dispos; 2008 Feb; 36(2):386-99. PubMed ID: 18006647
[TBL] [Abstract][Full Text] [Related]
19. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
[TBL] [Abstract][Full Text] [Related]
20. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.
Schulz HU; Hartmann M; Steinijans VW; Huber R; Lührmann B; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S51-7. PubMed ID: 8793603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
